Assessment of Psychological State in Patients with Polycystic Ovary Syndrome, and Psychological Management

doi:10.12280/gjszjk.20230325

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is one of the most common ovulatory disorders among women of reproductive age. Due to the endocrine and metabolic disorders, dissatisfaction for shape and appearance, infertility and other factors, women with PCOS have decreased life satisfaction and are more susceptible to the mood disorders such as anxiety and depression. Maternal excessive androgen and metabolic disorders are common features of PCOS, and cause an unfavorable intrauterine environment that disturb the development of hypothalamic neuroendocrine system and contribute to long-term behavioral, cognitive, and emotional disorders in their offspring. We summarized the psychological traits of PCOS, analyzed the methods for psychological assessment for PCOS. The cause and origin of psychological characteristics of PCOS women and their offspring were also discussed. We then summarized and analyzed related researches of psychological disorders in PCOS offspring. Finally, we outlined the therapeutic methods for psychological disorders of PCOS. Early diagnosis and intervention for PCOS-related psychiatric problems deserve keen attention in the future. It is recommended that PCOS patients should undergo screening for anxiety and depression. Timely diagnosis and follow-up management should be taken for patients with positive results. Through psychotherapy, lifestyle intervention, metabolic regulation, menstrual cycle adjustment and ovulation treatment, psychological problems and life quality can be improved.

Key words: Polycystic ovary syndrome, Anxiety, Depression, Psychometrics, Psychotherapy

XU Si-liang, MA Xiang, LIU Jia-yin, GAO Yan. Assessment of Psychological State in Patients with Polycystic Ovary Syndrome, and Psychological Management[J]. Journal of International Reproductive Health/Family Planning, 2023, 42(6): 481-486.

References 38

[1]	Siddiqui S, Mateen S, Ahmad R, et al. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS)[J]. J Assist Reprod Genet, 2022, 39(11):2439-2473. doi: 10.1007/s10815-022-02625-7.
[2]	Kolhe JV, Chhipa AS, Butani S, et al. PCOS and Depression: Common Links and Potential Targets[J]. Reprod Sci, 2022, 29(11):3106-3123. doi: 10.1007/s43032-021-00765-2.
[3]	Light RS, Chilcot J, McBride E. Psychological Distress in Women Living with Polycystic Ovary Syndrome: The Role of Illness Perceptions[J]. Womens Health Issues, 2021, 31(2):177-184. doi: 10.1016/j.whi.2020.11.003.
[4]	Doretto L, Mari FC, Chaves AC. Polycystic Ovary Syndrome and Psychotic Disorder[J]. Front Psychiatry, 2020, 11:543. doi: 10.3389/fpsyt.2020.00543. pmid: 32587538
[5]	Jiskoot G, van der Kooi AL, Busschbach J, et al. Cognitive behavioural therapy for depression in women with PCOS: systematic review and meta-analysis[J]. Reprod Biomed Online, 2022, 45(3):599-607. doi: 10.1016/j.rbmo.2022.05.001.
[6]	Thannickal A, Brutocao C, Alsawas M, et al. Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis[J]. Clin Endocrinol(Oxf), 2020, 92(4):338-349. doi: 10.1111/cen.14153.
[7]	Cesta CE, Månsson M, Palm C, et al. Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort[J]. Psychoneuroendocrinology, 2016, 73:196-203. doi: 10.1016/j.psyneuen.2016.08.005. pmid: 27513883
[8]	Mantzou D, Stamou MI, Armeni AK, et al. Impaired Sexual Function in Young Women with PCOS: The Detrimental Effect of Anovulation[J]. J Sex Med, 2021, 18(11):1872-1879. doi: 10.1016/j.jsxm.2021.09.004.
[9]	Akbari Sene A, Tahmasbi B, Keypour F, et al. Differences in and Correlates of Sexual Function in Infertile Women with and without Polycystic Ovary Syndrome[J]. Int J Fertil Steril, 2021, 15(1):65-72. doi: 10.22074/ijfs.2021.6206. pmid: 33497050
[10]	Berni TR, Morgan CL, Berni ER, et al. Polycystic Ovary Syndrome Is Associated With Adverse Mental Health and Neurodevelopmental Outcomes[J]. J Clin Endocrinol Metab, 2018, 103(6):2116-2125. doi: 10.1210/jc.2017-02667. pmid: 29648599
[11]	Karjula S, Morin-Papunen L, Auvinen J, et al. Psychological Distress Is More Prevalent in Fertile Age and Premenopausal Women With PCOS Symptoms: 15-Year Follow-Up[J]. J Clin Endocrinol Metab, 2017, 102(6):1861-1869. doi: 10.1210/jc.2016-3863. pmid: 28323926
[12]	Shi Y, Zhao H, Shi Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome[J]. Nat Genet, 2012, 44(9):1020-1025. doi: 10.1038/ng.2384. pmid: 22885925
[13]	Ryu KJ, Wi WY, Nam S, et al. Maternal Polycystic Ovary Syndrome and the Risk of Early Childhood Obesity in Female Offspring: A Nationwide Population-Based Study[J]. J Korean Med Sci, 2023, 38(14):e111. doi: 10.3346/jkms.2023.38.e111.
[14]	Smirnov VV, Beeraka NM, Butko DY, et al. Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS[J]. Reprod Sci, 2023, 30(3):772-786. doi: 10.1007/s43032-022-01013-x.
[15]	Silva MS, Prescott M, Campbell RE. Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS[J]. JCI Insight, 2018, 3(7):e99405. doi: 10.1172/jci.insight.99405.
[16]	Palm C, Glintborg D, Find LG, et al. Prenatal Androgen Exposure and Traits of Autism Spectrum Disorder in the Offspring: Odense Child Cohort[J]. J Autism Dev Disord, 2023, 53(3):1053-1065. doi: 10.1007/s10803-022-05446-w.
[17]	Cesta CE, Öberg AS, Ibrahimson A, et al. Maternal polycystic ovary syndrome and risk of neuropsychiatric disorders in offspring: prenatal androgen exposure or genetic confounding?[J]. Psychol Med, 2020, 50(4):616-624. doi: 10.1017/S0033291719000424. pmid: 30857571
[18]	Hu M, Richard JE, Maliqueo M, et al. Maternal testosterone exposure increases anxiety-like behavior and impacts the limbic system in the offspring[J]. Proc Natl Acad Sci U S A, 2015, 112(46):14348-14353. doi: 10.1073/pnas.1507514112.
[19]	Stener-Victorin E, Manti M, Fornes R, et al. Origins and Impact of Psychological Traits in Polycystic Ovary Syndrome[J]. Med Sci (Basel), 2019, 7(8):86. doi: 10.3390/medsci7080086.
[20]	Yin X, Ji Y, Chan C, et al. The mental health of women with polycystic ovary syndrome: a systematic review and meta-analysis[J]. Arch Womens Ment Health, 2021, 24(1):11-27. doi: 10.1007/s00737-020-01043-x.
[21]	Levis B, Sun Y, He C, et al. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis[J]. JAMA, 2020, 323(22):2290-2300. doi: 10.1001/jama.2020.6504. pmid: 32515813
[22]	Kodipalli A, Devi S. Prediction of PCOS and Mental Health Using Fuzzy Inference and SVM[J]. Front Public Health, 2021, 9:789569. doi: 10.3389/fpubh.2021.789569.
[23]	中华医学会行为医学分会, 中华医学会行为医学分会认知应对治疗学组. 抑郁症治疗与管理的专家推荐意见(2022年)[J]. 中华行为医学与脑科学杂志, 2023, 32(3):193-202. doi: 10.3760/cma.j.cn371468-20220921-00563.
[24]	中国神经科学学会精神病学基础与临床分会抑郁障碍研究联盟. 伴焦虑痛苦特征抑郁症的临床诊治专家共识[J]. 精神医学杂志, 2021, 34(1):74-78. doi: 10.3969/j.issn.2095-9346.2021.01.018.
[25]	Majidzadeh S, Mirghafourvand M, Farvareshi M, et al. The effect of cognitive behavioral therapy on depression and anxiety of women with polycystic ovary syndrome: a randomized controlled trial[J]. BMC Psychiatry, 2023, 23(1):332. doi: 10.1186/s12888-023-04814-9. pmid: 37170227
[26]	Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Hum Reprod, 2018, 33(9):1602-1618. doi: 10.1093/humrep/dey256.
[27]	Masoudi M, Ansari S, Kashani L, et al. Effect of sertraline on depression severity and prolactin levels in women with polycystic ovary syndrome: a placebo-controlled randomized trial[J]. Int Clin Psychopharmacol, 2021, 36(5):238-243. doi: 10.1097/YIC.0000000000000367.
[28]	Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Fertil Steril, 2018, 110(3):364-379. doi: 10.1016/j.fertnstert.2018.05.004. pmid: 30033227
[29]	Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome[J]. Lancet Diabetes Endocrinol, 2022, 10(9):668-680. doi: 10.1016/S2213-8587(22)00163-2.
[30]	Lie Fong S, Douma A, Verhaeghe J. Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): how to achieve weight loss in overweight and obese women with PCOS?[J]. J Gynecol Obstet Hum Reprod, 2021, 50(6):101894. doi: 10.1016/j.jogoh.2020.101894.
[31]	Wu Y, Tu M, Huang Y, et al. Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis[J]. JAMA Netw Open, 2020, 3(8):e2011995. doi: 10.1001/jamanetworkopen.2020.11995.
[32]	Tso LO, Costello MF, Albuquerque L, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome[J]. Cochrane Database Syst Rev, 2020, 12(12):CD006105. doi: 10.1002/14651858.CD006105.pub4.
[33]	Wang Z, Zhao J, Ma X, et al. Effect of Orlistat on Live Birth Rate in Overweight or Obese Women Undergoing IVF-ET: A Randomized Clinical Trial[J]. J Clin Endocrinol Metab, 2021, 106(9):e3533-e3545. doi: 10.1210/clinem/dgab340.
[34]	Bhide P, Pundir J, Gudi A, et al. The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis[J]. Acta Obstet Gynecol Scand, 2019, 98(10):1235-1244. doi: 10.1111/aogs.13625.
[35]	Cantelmi T, Lambiase E, Unfer VR, et al. Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women[J]. Eur Rev Med Pharmacol Sci, 2021, 25(5):2383-2389. doi: 10.26355/eurrev_202103_25278.
[36]	Ovarian Stimulation T, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI[J]. Hum Reprod Open, 2020, 2020(2): hoaa009. doi: 10.1093/hropen/hoaa009.
[37]	多囊卵巢综合征相关不孕治疗及生育保护共识专家组, 中华预防医学会生育力保护分会生殖内分泌生育保护学组. 多囊卵巢综合征相关不孕治疗及生育保护共识[J]. 生殖医学杂志, 2020, 29(7):843-851. doi: 10.3969/j.issn.1004-3845.2020.07.002.
[38]	Fernandez RC, Moore VM, Rumbold AR, et al. Diagnosis delayed: health profile differences between women with undiagnosed polycystic ovary syndrome and those with a clinical diagnosis by age 35 years[J]. Hum Reprod, 2021, 36(8):2275-2284. doi: 10.1093/humrep/deab101.